EMA/233269/2020

European Medicines Agency decision

P/0184/2020

of 13 May 2020

on the acceptance of a modification of an agreed paediatric investigation plan for afatinib (Giotrif), (EMEA-001596-PIP02-17-M02) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0184/2020

of 13 May 2020

on the acceptance of a modification of an agreed paediatric investigation plan for afatinib (Giotrif), (EMEA-001596-PIP02-17-M02) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the European Medicines Agency's decision P/0320/2018 issued on 12 September 2018, and the decision P/0235/2019 issued on 16 July 2019,

Having regard to the application submitted by Boehringer Ingelheim International GmbH on 20 December 2019 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and proposing a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 27 March 2020, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan and to the deferral and on the granting of a waiver.

(2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan, including changes to the deferral.

(3) It is therefore appropriate to adopt a decision granting a waiver.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for afatinib (Giotrif), film-coated tablet, capsules and solvent for oral solution, oral use, including changes to the deferral, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

A waiver for afatinib (Giotrif), film-coated tablet, capsules and solvent for oral solution, oral use, the details of which are set out in the opinion of the Paediatric Committee the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

This decision is addressed to Boehringer Ingelheim International GmbH, Binger Strasse 173, 55216 - Ingelheim, Germany.

EMA/PDCO/31840/2020
Amsterdam, 27 March 2020

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan

EMEA-001596-PIP02-17-M02

Scope of the application

Active substance(s):

Afatinib

Invented name:

Giotrif

Condition(s):

Treatment of all conditions included in the category of malignant neoplasms (except central nervous system, haematopoietic and lymphoid tissue neoplasms)

Treatment of malignant neoplasms of the central nervous system

Authorised indication(s):

See Annex II

Pharmaceutical form(s):

Film-coated tablet

Capsules and solvent for oral solution

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

Boehringer Ingelheim International GmbH

Information about the authorised medicinal product:

See Annex II

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Boehringer Ingelheim International GmbH submitted to the European Medicines Agency on 20 December 2019 an application for modification of the agreed paediatric investigation plan with a deferral as set out in the European Medicines Agency's decision P/0320/2018 issued on 12 September 2018, and the decision P/0235/2019 issued on 16 July 2019.

The application for modification proposed changes to the agreed paediatric investigation plan and to the deferral and proposed a waiver.

The procedure started on 28 January 2020.

Scope of the modification

Some measures and timelines of the Paediatric Investigation Plan have been modified. A waiver for a new paediatric subset has been added.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree to changes to the paediatric investigation plan and to the deferral in the scope set out in the Annex I of this opinion;
   - to grant a waiver for one or more subsets of the paediatric population concluded in accordance with Article 11(1)(a) of said Regulation, on the grounds that the specific medicinal product is likely to be ineffective or unsafe in part or all of the paediatric population.

   The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition:

Treatment of all conditions included in the category of malignant neoplasms (except central nervous system, haematopoietic and lymphoid tissue neoplasms).

The waiver applies to:

- the paediatric population from birth to less than 1 year of age;
- film-coated tablet, capsules and solvent for oral solution, oral use;
- on the grounds that the specific medicinal product is likely to be ineffective.

1.2. Condition:

Treatment of malignant neoplasms of the central nervous system

The waiver applies to:

- the paediatric population from birth to less than 1 year of age;
- film-coated tablet, capsules and solvent for oral solution, oral use;
- on the grounds that the specific medicinal product is likely to be ineffective.

2. Paediatric investigation plan

2.1. Condition

Treatment of all conditions included in the category of malignant neoplasms (except central nervous system, haematopoietic and lymphoid tissue neoplasms)

2.1.1. Indication(s) targeted by the PIP

Treatment of paediatric patients with a recurrent or refractory or newly-diagnosed solid tumour (excluding central nervous system tumours) with known ErbB deregulation

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 1 year of age to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Film-coated tablet

Capsules and solvent for oral solution

2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	0	Not applicable.
Non-clinical studies	1	**Study 1** Non-clinical biomarker study in paediatric tumour samples.
Clinical studies	2	**Study 2** Open label, single-arm dose escalation trial to assess the safety, pharmacokinetic and anti-tumour activity of afatinib used in monotherapy in paediatric patients from 1 year to less than 18 years of age with a recurrent/refractory solid tumour with known ErbB pathway deregulation, including a dose finding part to determine the maximum-tolerated dose (part 1) and an expansion part to assess the anti-tumour activity of afatinib (part 2) (Study 1200.120). **Study 3** deleted in modification EMEA-001596-PIP02-17-M02.
Extrapolation, modelling and simulation studies	0	Not applicable
Other studies	0	Not applicable
Other measures	0	Not applicable

2.2. Condition

Treatment of malignant neoplasms of the central nervous system

2.2.1. Indication(s) targeted by the PIP

Treatment of paediatric patients with a recurrent or refractory or newly-diagnosed central nervous system tumour with known ErbB deregulation

2.2.2. Subset(s) of the paediatric population concerned by the paediatric development

From 1 year of age to less than 18 years of age

2.2.3. Pharmaceutical form(s)

Film-coated tablet

Capsules and solvent for oral solution

2.2.4. Measures

Area	Number of measures	Description
Quality-related studies	0	Not applicable
Non-clinical studies	1	**Study 1** Same as for condition 'Treatment of all conditions included in the category of malignant neoplasms (except central nervous system, haematopoietic and lymphoid tissue neoplasms)'
Clinical studies	2	**Study 2** Same as for condition 'Treatment of all conditions included in the category of malignant neoplasms (except central nervous system, haematopoietic and lymphoid tissue neoplasms)' **Study 3** deleted in modification EMEA-001596-PIP02-17-M02.
Extrapolation, modelling and simulation studies	0	Not applicable
Other studies	0	Not applicable
Other measures	0	Not applicable

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By December 2020
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Condition(s) and authorised indication(s):

1. Treatment of all conditions included in the category of malignant neoplasms (except central nervous system, haematopoietic and lymphoid tissue neoplasms)

Authorised indication(s):

- GIOTRIF as monotherapy is indicated for the treatment of Epidermal Growth Factor Receptor (EGFR) TKI-naïve adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutation(s)
- GIOTRIF as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC of squamous histology progressing on or after platinum-based chemotherapy

Authorised pharmaceutical form(s):

Film-coated tablet

Authorised route(s) of administration:

Oral use